MAVENIR
27.5.2021 15:02:13 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, has announced support for deployments and integration of cloud-native telecom network functions with telco infrastructure solutions on Amazon Web Services, Inc. (AWS).
Mavenir’s collaboration with AWS allows Communications Service Providers (CSPs) to deploy Mavenir’s market leading 4G and 5G products and applications with AWS’s computing infrastructure, state of the art container deployment and management technologies, and big data analytics services. The solution is designed to scale and leverages the same tools and technologies offered by AWS to enterprise applications today. These tools are the backbone for visibility and automation for any AWS-based offering and generally referred to as Platform-as-a-Service (PaaS). This translates to offloading some of the telco application business to cloud functions, reducing complexity and putting service providers at par with organizations enjoying cost savings from cloud migrations without losing insight, performance, and control on their networks.
Another key element from this collaboration is the enablement of Private Networks and Edge deployments on AWS, powered by Mavenir’s Digital Enablement platform . With a digital app store for enterprise and various industry 4.0 applications such as IVA, AR/VR, IIoT and Robotics control, Mavenir’s Edge AI application suite is empowering an ecosystem of developers, service providers, partners, and enterprises to create and deploy applications in AWS to power digitalization and industry 4.0 with 5G.
This collaboration also lowers the network deployment time and cost for MNOs and enterprises equally fulfilling use cases of either adding 5G and edge capabilities to an existing network or a greenfield 4G/5G network launch leveraging public clouds.
“The collaboration with Mavenir and AWS allows us to build out our 5G network and messaging platforms in a true cloud-native manner, harnessing the speed and agility that the AWS cloud brings along with Mavenir’s expertise in deploying and operating cloud-native network functions," said Sidd Chenumolu, Vice President of Technology Development, DISH. “Together, we will enable our customers to take full advantage of the potential of 5G, reimagining wireless connectivity and giving our customers the ability to customize their network experience.”
“Working with AWS enables us to bring new customer-focused 5G use cases and 5G deployments to the market faster and with unique capabilities to realize true 5G potential,” said Bejoy Pankajakshan, Mavenir’s Chief Strategy Officer. “Mavenir’s solutions are designed to support full public cloud as well as hybrid cloud deployments.”
"We’re delighted to collaborate with Mavenir to offer voice and messaging solutions for core network and RAN customers along with AI/ML solutions for orchestration and observability,” said Amir Rao, General Manager Telco Solution Portfolio and Tech Alliances, AWS. “Together, we are providing true cloud native benefits to CSP customers, combining Mavenir’s expertise in the NFV market with the global scale of the AWS infrastructure to meet industry challenges of agility, scaling, slicing, and resiliency.”
Mavenir’s 4G and 5G deployments on AWS provides unique capabilities, including:
- Integration of Mavenir’s cloud-native Open RAN (vDU, vCU-CP, vCU-UP), Converged 4G/5G Packet Core, IMS, and Messaging with Amazon Elastic Kubernetes Service (Amazon EKS) anywhere supporting AWS Outposts.
- Use of AWS platform services and tools to deploy and manage cloud native network functions.
- Options for existing deployments to migrate Mavenir’s IMS core, voice, and messaging solutions to Amazon EKS and Amazon Elastic Compute Cloud (Amazon EC2) infrastructure.
- Mavenir’s Orchestration and Network Slicing solutions to manage hybrid cloud workloads running on AWS.
- Adoption of AWS for centrally managed telco workloads on far-edge, network edge and core simultaneously.
- Deployment of Mavenir’s standards compliant observability framework, RIC, NWDAF, AIOps and Analytics platform in AWS to collect the data from various AWS nodes in a centrally managed data lake and process the data using AI/ML for network wide insights and optimization.
- Integration of Mavenir’s telecom adaptation layer (Telco PaaS) as a common open source-based platform adaptation layer designed for telco specific workloads to support various carrier grade requirements on top of Amazon EKS and AWS PaaS functions.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005102/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom